Efficacy of Intravenous Immunoglobulin Therapy in Childhood Atopic Dermatitis

2012 ◽  
Vol 18 (1) ◽  
pp. 26-31
Author(s):  
Eun Kyeong Yeon ◽  
A Young Park ◽  
Sanghoon Chae ◽  
Seung Soo Kim ◽  
Kyeong Bae Park ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
Intravenous Immunoglobulin Therapy

scholarly journals Transient Hypogammaglobulinemia and Severe Atopic Dermatitis: Open-label Treatment with Immunoglobulin in a Case Series

2016 ◽  
Vol 7 (2) ◽  
pp. ar.2016.7.0164 ◽  
Author(s):  
Moira E. Breslin ◽  
Joanna H. Lin ◽  
Robert Roberts ◽  
Kellie J. Lim ◽  
E. Richard Stiehm
Keyword(s):  
Atopic Dermatitis ◽  
Los Angeles ◽  
Intravenous Immunoglobulin ◽  
Conventional Therapy ◽  
Case Series ◽  
Retrospective Chart Review ◽  
Immunoglobulin Therapy ◽  
Severe Atopic Dermatitis ◽  
Open Label ◽  
Intravenous Immunoglobulin Therapy

Background We reported on six infants between 5 and 11 months old, with transient hypogammaglobulinemia of infancy and severe refractory atopic dermatitis, who were treated with open-label immunoglobulin (Ig) after conventional therapy failed. All six infants had an IgG level of <225 mg/dL, elevated eosinophil and IgE levels, and no urine or stool protein losses, but they did exhibit hypoalbuminemia. Objective To evaluate the utility of open-label immunoglobulin in infants with severe atopic dermatitis for whom conventional therapy failed. We reviewed the clinical utility of intravenous immunoglobulin in the treatment of severe atopic dermatitis, the most recent research in the field, and suggested mechanisms for its benefit. Methods The six infants were identified from a retrospective chart review at the University of California Los Angeles Allergy and Immunology outpatient pediatric clinic. Results All six patients were treated with 400 mg/kg/month of intravenous immunoglobulin and had normalization of their IgG and albumin levels, and all but one had clinically improved atopic dermatitis. Conclusion Infants with severe atopic dermatitis who did not respond to conventional therapy avoidance may benefit from intravenous immunoglobulin therapy.

Pulmonary Thromboembolism Induced by Intravenous Immunoglobulin Therapy for Stevens-Johnson Syndrome : A Case Report

2019 ◽  
Vol 81 (3) ◽  
pp. 170-174 ◽  
Author(s):  
Taketoshi IDE ◽  
Maiko OHNO ◽  
Takamichi ITO ◽  
Karin TSUKAMOTO ◽  
Anna HIRANO ◽  
...  
Keyword(s):  
Case Report ◽  
Intravenous Immunoglobulin ◽  
Pulmonary Thromboembolism ◽  
Immunoglobulin Therapy ◽  
Stevens Johnson Syndrome ◽  
Intravenous Immunoglobulin Therapy ◽  
Johnson Syndrome
Sign in / Sign up

Export Citation Format

Share Document